ImmunoQuest Therapeutics is a preclinical biopharmaceutical company specializing in precision oncology. We are developing antibody-drug conjugates (ADCs) that target p95HER2; a hyperactive, tumor-specific isoform of HER2 associated with metastatic progression and resistance to current HER2-directed therapies.

Our lead program, NAZ-001, is a first-in-class ADC designed to treat HER2-positive breast cancer, where approximately 80% of tumors express p95HER2. Because p95HER2 lacks the binding domain required for existing HER2 therapies (such as trastuzumab, Kadcyla, and Enhertu), patients with this biomarker often have limited treatment options and poor outcomes. NAZ-001 is engineered to selectively target p95HER2, offering a highly specific, tumor-selective, and potentially safer therapeutic approach.

Beyond breast cancer, p95HER2 is also expressed in other HER2+ tumors, including but not limited to ovarian, lung, endometrial, and colorectal cancers, creating a broad clinical and commercial opportunity.

With a differentiated mechanism of action, a tumor-specific target, and strong potential across multiple indications, ImmunoQuest is addressing a critical unmet need in oncology and advancing a new generation of HER2-targeted therapies for patients with limited alternatives.

Immunoquest Therapeutics

Org chart

Teams

Offices